Daily Medication Pearl: Durvalumab (Imfinzi) for Non-Small Cell Lung Cancer

Medication Pearl of the Day: Durvalumab (Imfinzi)

Indication: Imfinzi is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of adult patients with unresectable, stage III non-small cell lung cancer (NSCLC).

Insight:

• Dosing: 10 mg/kg every 2 weeks or 1500 mg every 4 weeks.
• Dosage form: Injection 500 mg/10 mL (50 mg/mL) solution in a single-dose vial. Injection 120 mg/2.4 mL (50 mg/mL) solution in a single-dose vial.
• Adverse events (AEs): Most common AEs were cough, fatigue, pneumonitis/radiation pneumonitis, upper respiratory tract infections, dyspnea, and rash.
• Mechanism of action: Durvalumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 (B7.1). Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses, without inducing antibody dependent cell-mediated cytotoxicity.
• Manufacturer: AstraZeneca

Sources:

https://www.azpicentral.com/pi.html?product=imfinzi

imfinzi - Google Search